Why the study?
Periostin is involved in periodontal integrity affected by periodontal disease, but changes in GCF and salivary levels following non-surgical therapy needed evaluation.
Does non-surgical periodontal therapy alter GCF and salivary periostin levels in patients with chronic periodontitis?
Does non-surgical periodontal therapy alter GCF and salivary periostin levels in patients with chronic periodontitis?
Non-surgical periodontal therapy significantly alters GCF and salivary periostin levels, suggesting their potential as biomarkers for periodontal disease activity.
Periostin levels may track periodontal therapy response; hypothesis-generating and requires validation before clinical use.
Introduction: Periostin is a matricellular protein highly expressed by the fibroblasts in the periodontal ligament. It is entangled in the maintenance of periodontal integrity which is affected by periodontal disease.Aim: this study aimed to compare both GCF and salivary periostin levels during periodontal disease to their levels after non- surgical periodontal therapy.Subjects and methods: The present study was performed on a total of 30 subjects, 13 males and 17 females. The thirty selected participants were sampled at baseline and after receiving the non-surgical periodontal treatment.Results: In GCF, there was a statistically significant (at P ≤ 0.05) increase in mean Periostin level after treatment. While in saliva, there was a statistically significant (at P ≤0.05) decrease in mean Periostin level after treatment. Conclusion Our results suggested that GCF periostin level may be considered as a reliable marker in the evaluation of periodontal disease activity, while salivary periostin level could have a promising diagnostic potential. So, further investigations are recommended.
No takes yet. Share an insight, caveat, or question.
Hussien et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: